Tryptophan
CAS 73-22-3
Tryptophan (CAS 73-22-3) is a Phase 4 pharmaceutical compound with 3 bioactivity targets and 18 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24226.294444444444 nM | 32 | - |
| - | IC50 | 16009.389411764705 nM | 16 | - |
| - | MIC | 5.736666666666667 ug.mL-1 | 6 | - |
| Extracellular calcium-sensing receptor GPCR |
Kd | 4.4 | - | Homo sapiens |
| Myeloperoxidase Enzyme |
IC50 | 5.65 | - | Homo sapiens |
| Probable G-protein coupled receptor 139 GPCR |
IC50 | 4.59 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Bronchial hyperreactivity | 15 | 69.577 | 10066091 |
| Breast disorder | 13 | 60.911 | 10061021 |
| Foetal growth restriction | 15 | 48.226 | 10070531 |
| Ejaculation failure | 7 | 37.799 | 10014328 |
| Genital hypoaesthesia | 6 | 37.414 | 10068912 |
| Serotonin syndrome | 17 | 37.342 | 10040108 |
| Infantile apnoea | 8 | 35.493 | 10077321 |
| Device related sepsis | 10 | 35.386 | 10069802 |
| Selective eating disorder | 8 | 30.852 | 10078069 |
| Loss of libido | 6 | 21.947 | 10024870 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| GPR139 GPR139 |
Agonist | 4.590000152587891 pIC50 | 26349500 |
| GPR139 GPR139 |
Agonist | 3.6600000858306885 pEC50 | 24826842 |
| GPR139 GPR139 |
Agonist | 3.130000114440918 pKi | 26349500 |
| CaS receptor CASR |
Positive | 2.6 pKd | 10781086|15234970 |
| Proton-coupled Amino acid Transporter 1 SLC36A1 |
Inhibition | 2.3 pKi | 16126914 |
Pharmacogenomics
Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TRYPTOPHAN | 10898 | SU | MTHSPL |
| tryptophan | 10898 | IN | RXNORM |
| L-tryptophan | 10898 | SY | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tryptophan used for in pharmaceutical contexts?
Tryptophan (CAS 73-22-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tryptophan?
Tryptophan has 18 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Bronchial hyperreactivity, Breast disorder, Foetal growth restriction, Ejaculation failure, Genital hypoaesthesia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tryptophan also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for L-Tryptophan with EU status "permitted".
What clinical phase is Tryptophan in?
Tryptophan is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Tryptophan?
Tryptophan has 6 bioactivity rows in this page query. Rendered target entries include Extracellular calcium-sensing receptor, Myeloperoxidase, Probable G-protein coupled receptor 139.